Halozyme Therapeutics (HALO) Competitors

$70.03 -0.90 (-1.27%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$70.50 +0.47 (+0.68%)

As of 07:42 AM Eastern

HALO vs. BIIB, UTHR, INCY, NBIX, and IONS

Should you buy Halozyme Therapeutics stock or one of its competitors? MarketBeat compares Halozyme Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Biogen?

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Halozyme Therapeutics has a net margin of 23.13% compared to Biogen's net margin of 13.81%. Halozyme Therapeutics' return on equity of 187.91% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Biogen	13.81%	12.83%	8.01%

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.51B	5.50	$316.89M	$2.78	25.19
Biogen	$9.94B	3.04	$1.29B	$9.32	21.95

Halozyme Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Halozyme Therapeutics presently has a consensus target price of $80.67, indicating a potential upside of 15.19%. Biogen has a consensus target price of $214.23, indicating a potential upside of 4.74%. Given Halozyme Therapeutics' higher probable upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Biogen. MarketBeat recorded 31 mentions for Halozyme Therapeutics and 27 mentions for Biogen. Biogen's average media sentiment score of 0.91 beat Halozyme Therapeutics' score of 0.59 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	12 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics beats Biogen on 10 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

United Therapeutics has a net margin of 40.62% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Halozyme Therapeutics	23.13%	187.91%	21.92%

United Therapeutics has higher revenue and earnings than Halozyme Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.17B	7.76	$1.33B	$27.09	21.39
Halozyme Therapeutics	$1.51B	5.50	$316.89M	$2.78	25.19

United Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

United Therapeutics currently has a consensus target price of $619.42, indicating a potential upside of 6.88%. Halozyme Therapeutics has a consensus target price of $80.67, indicating a potential upside of 15.19%. Given Halozyme Therapeutics' higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Halozyme Therapeutics had 1 more articles in the media than United Therapeutics. MarketBeat recorded 31 mentions for Halozyme Therapeutics and 30 mentions for United Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.59 beat United Therapeutics' score of 0.39 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

United Therapeutics and Halozyme Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

97.0% of Incyte shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Incyte has a net margin of 26.71% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Incyte has higher revenue and earnings than Halozyme Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.84	$1.29B	$7.08	13.96
Halozyme Therapeutics	$1.51B	5.50	$316.89M	$2.78	25.19

In the previous week, Halozyme Therapeutics had 19 more articles in the media than Incyte. MarketBeat recorded 31 mentions for Halozyme Therapeutics and 12 mentions for Incyte. Incyte's average media sentiment score of 0.78 beat Halozyme Therapeutics' score of 0.59 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Halozyme Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Incyte currently has a consensus target price of $104.26, indicating a potential upside of 5.51%. Halozyme Therapeutics has a consensus target price of $80.67, indicating a potential upside of 15.19%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Halozyme Therapeutics beats Incyte on 9 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 23.13% compared to Neurocrine Biosciences' net margin of 21.55%. Halozyme Therapeutics' return on equity of 187.91% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Neurocrine Biosciences has higher revenue and earnings than Halozyme Therapeutics. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.67	$478.60M	$6.49	24.86
Halozyme Therapeutics	$1.51B	5.50	$316.89M	$2.78	25.19

In the previous week, Halozyme Therapeutics had 18 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 31 mentions for Halozyme Therapeutics and 13 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.86 beat Halozyme Therapeutics' score of 0.59 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Neurocrine Biosciences currently has a consensus price target of $184.15, suggesting a potential upside of 14.15%. Halozyme Therapeutics has a consensus price target of $80.67, suggesting a potential upside of 15.19%. Given Halozyme Therapeutics' higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Neurocrine Biosciences beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Halozyme Therapeutics has a net margin of 23.13% compared to Ionis Pharmaceuticals' net margin of -30.91%. Halozyme Therapeutics' return on equity of 187.91% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Halozyme Therapeutics	23.13%	187.91%	21.92%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.6% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 24 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 31 mentions for Halozyme Therapeutics and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.18 beat Halozyme Therapeutics' score of 0.59 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals currently has a consensus price target of $99.35, suggesting a potential upside of 28.03%. Halozyme Therapeutics has a consensus price target of $80.67, suggesting a potential upside of 15.19%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Halozyme Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	13.58	-$381.39M	-$2.07	N/A
Halozyme Therapeutics	$1.51B	5.50	$316.89M	$2.78	25.19

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.40B	$3.42B	$6.31B	$12.28B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	25.19	18.67	21.03	25.58
Price / Sales	5.50	301.04	552.34	78.22
Price / Cash	14.87	122.51	42.94	55.34
Price / Book	37.85	6.75	9.83	6.66
Net Income	$316.89M	$24.11M	$3.55B	$333.63M
7 Day Performance	7.42%	-0.53%	-0.52%	-0.12%
1 Month Performance	4.04%	0.34%	1.20%	3.93%
1 Year Performance	46.17%	78.62%	41.25%	36.07%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	3.9296 of 5 stars	$70.03 -1.3%	$80.67 +15.2%	+39.4%	$8.40B	$1.51B	25.19	390	Trending News Earnings Report Analyst Forecast Insider Trade
BIIB Biogen	3.0642 of 5 stars	$187.21 +0.1%	$214.23 +14.4%	+66.1%	$27.62B	$9.89B	20.09	7,500
UTHR United Therapeutics	3.5498 of 5 stars	$581.22 +1.9%	$601.50 +3.5%	+88.1%	$25.00B	$3.18B	20.83	1,400	Insider Trade
INCY Incyte	4.5351 of 5 stars	$97.14 +0.2%	$104.26 +7.3%	+62.5%	$19.36B	$5.14B	13.72	2,844
NBIX Neurocrine Biosciences	3.6511 of 5 stars	$134.07 +1.7%	$180.45 +34.6%	+38.0%	$13.25B	$2.86B	28.77	2,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. BIIB, UTHR, INCY, NBIX, and IONS

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Summary

How does Halozyme Therapeutics compare to Incyte?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Summary

How does Halozyme Therapeutics compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. BIIB, UTHR, INCY, NBIX, and IONS

How does Halozyme Therapeutics compare to Biogen?

Is HALO or BIIB more profitable?

Which has preferable earnings & valuation, HALO or BIIB?

Which has more risk & volatility, HALO or BIIB?

Do analysts rate HALO or BIIB?

Does the media favor HALO or BIIB?

Do insiders & institutionals believe in HALO or BIIB?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Is UTHR or HALO more profitable?

Which has higher valuation & earnings, UTHR or HALO?

Which has more volatility & risk, UTHR or HALO?

Do analysts prefer UTHR or HALO?

Does the media prefer UTHR or HALO?

Do institutionals & insiders believe in UTHR or HALO?

Summary

How does Halozyme Therapeutics compare to Incyte?

Do insiders and institutionals believe in INCY or HALO?

Is INCY or HALO more profitable?

Which has better valuation and earnings, INCY or HALO?

Does the media prefer INCY or HALO?

Which has more volatility and risk, INCY or HALO?

Do analysts prefer INCY or HALO?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Do institutionals & insiders hold more shares of NBIX or HALO?

Is NBIX or HALO more profitable?

Which has better earnings and valuation, NBIX or HALO?

Does the media prefer NBIX or HALO?

Which has more risk & volatility, NBIX or HALO?

Do analysts prefer NBIX or HALO?

Summary

How does Halozyme Therapeutics compare to Ionis Pharmaceuticals?

Is IONS or HALO more profitable?

Do institutionals & insiders hold more shares of IONS or HALO?

Does the media prefer IONS or HALO?

Do analysts prefer IONS or HALO?

Which has better earnings and valuation, IONS or HALO?

Which has more risk & volatility, IONS or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools